top of page

Christophe Weber describes Takeda's global perspective on R&D and business development

Takeda's CEO talks about the $4B+ Nimbus acquisition, recent approvals, and what's ahead for the company in 2024.





Comentarios


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page